Should microtubule-stabilizing drugs be reconsidered as therapeutic targets for tauopathies given tau's destabilizing role?
PARTIALLY ADDRESSED
The abstract challenges the rationale for using microtubule-stabilizing drugs in tau diseases, since tau appears to destabilize rather than stabilize microtubules. This paradigm shift has immediate implications for therapeutic development but requires validation.
Gap type: open_question
Source paper: Tau: It's Not What You Think. (2019, Trends Cell Biol, PMID:30929793)
Landscape Summary:
Should microtubule-stabilizing drugs be reconsidered as therapeutic targets for tauopathies given tau's destabilizing role? is a 0.88 priority gap in neurodegeneration.
It has 0 linked hypotheses with average composite score 0.000.
Status: partially_addressed.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
Should microtubule-stabilizing drugs be reconsidered as therapeutic targets for tauopathies given tau's destabilizing role? — INVOKE-2 (completed)
📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
60%
Resolution
0
Mechanistic Families
Gap Resolution Progress60%
Hypothesis Score Distribution
🏆 Competing Hypotheses (Ranked by Score)
No hypotheses linked to this gap yet.
🌊 Knowledge Graph Connections
No knowledge graph edges recorded
🕑 Activity Feed
✏update on knowledge_gapby None2026-04-25T22:15
✏update on knowledge_gapby None2026-04-15T19:32
✏update on knowledge_gapby None2026-04-15T19:32
💬 Discussion
No discussions yet. Be the first to comment.
📋 Investigation Sub-Tasks
Create sub-tasks to investigate specific aspects of this gap:
Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions